Guggenheim Initiates Coverage On CG Oncology with Buy Rating, Announces Price Target of $90
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Guggenheim analyst Brad Canino initiates coverage on CG Oncology (NASDAQ:CGON) with a Buy rating and announces Price Target of $90.
Guggenheim analyst Brad Canino initiates coverage on CG Oncology (NASDAQ:CGON) with a Buy rating and announces Price Target of $90.